Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

45706

Supelco

Warfarin

PESTANAL®, analytical standard

Synonym(s):

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H16O4
CAS Number:
81-81-2
Molecular Weight:
308.33
Beilstein:
8868198
EC Number:
201-377-6
MDL number:
MFCD00006854
UNSPSC Code:
41116107
PubChem Substance ID:
329756915
NACRES:
NA.24

grade

analytical standard

Quality Level

100

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

162-164 °C (lit.)

application(s)

agriculture
environmental

format

neat

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

Gene Information

human ... VKORC1(79001)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Warfarin is an anticoagulant commonly used in the prevention of thrombosis and thromboembolism. Its use is studied in stroke and pulmonary fibrosis patients among many others. It is used to study potential risks and interactions with other drugs and food.

Biochem/physiol Actions

Warfarin consists of a racemic mixture of two active enantiomers, R- and S- forms. Warfarin is slower-acting than the common anticoagulant heparin. Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the calcium-dependent clotting factors II, VII, IX and X. It inhibits regulatory factors protein C, protein S, and protein Z.

Caution

Restricted to professional users. Attention − Avoid exposure − obtain special instructions before use.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Signal Word

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

Target Organs

Blood

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM4467
BCCH4004
BCBV7416
BCBV3285
SZBF197XV

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 1

1 of 1

Candesartan Cilexetil Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1854

Candesartan Cilexetil

A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
Shinji Kamisuki et al.
Journal of medicinal chemistry, 54(13), 4923-4927 (2011-05-13)
Fatostatin, a recently discovered small molecule that inhibits activation of sterol regulatory element-binding protein (SREBP), blocks biosynthesis and accumulation of fat in obese mice. We synthesized and evaluated a series of fatostatin derivatives. Our structure-activity relationships led to the identification
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Matthew W Sherwood et al.
Circulation, 129(18), 1850-1859 (2014-02-21)
During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteristics of patients undergoing TI, and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service